Investigational Product

COMBINATION_PRODUCT2 trials

Sponsors

Becton, Dickinson and Company, Telavant, Inc.

Conditions

Crohn DiseaseMicrobial Colonization

Phase 2

Study to Evaluate the Efficacy and Safety of PF-06480605 in Adult Participants With Moderate to Severe Crohn's Disease

WithdrawnNCT05471492

Telavant, Inc.Crohn Disease

Start: 2023-07-30End: 2026-08-15Updated: 2023-10-19

Unknown Phase

Evaluation of the Antimicrobial Effectiveness of CHG/IPA

CompletedNCT04035161

Becton, Dickinson and CompanyMicrobial Colonization

Start: 2019-04-17End: 2019-12-24Updated: 2021-08-17

Related Papers

Japanese Phase 1 Study for Global Development of Anti‐<scp>TL1A</scp> Antibody <scp>PF</scp>‐06480605: A Randomized, Placebo‐Controlled, Single‐Ascending Dose Study

Clinical and Translational Science2025-03-011 citations